Steven R. Deitcher

Steven has more than 25 years of life sciences product discovery and development experience. He was most recently co-founder and CEO for Medeor Therapeutics, where he advanced the first cellular therapy to induce immune tolerance in solid organ transplant recipients into Phase 3 development. Prior to that he was CEO of Talon Therapeutics (OTC: TLON) where he was responsible for the approval of the anti-leukemia drug, Marqibo®, and sale to Spectrum Pharmaceuticals(NASDAQ: SPPI). Prior to that he was VP and Chief Medical Scientist at Nuvelo (NASDAQ: NUVO). He was formerly the head of hematology and coagulation medicine at the Cleveland Clinic. Steven received his MD from Northwestern, completed his residency training at Washington University/Barnes Hospital, and completed hematology and medical oncology fellowships at Tufts/New England Medical Center.